Drugs / Autologous CD19 CAR+ EGFTt + T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01683279 | Mar 2012 → Jan 2015 overdue | B-cell non-Hodgkin lymphoma | Seattle Children's Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CD19 CAR+ EGFTt + T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01683279 ↗ |
| Action | Deplete | “The CAR enables the T cell to recognize and kill the leukemic cells though the recognition of CD19, a protein expressed on the surface of the majority of pediatric ALL.” NCT01683279 ↗ |
| Modality | Cell therapy | “genetically modified autologous T cells” NCT01683279 ↗ |